End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- AUD | -.--% | -.--% | -.--% |
04-19 | INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test | MT |
04-15 | Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares | MT |
Valuation
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 78.22 | 46.01 | - | - |
Enterprise Value (EV) 1 | 78.22 | 38.91 | 37.11 | 39.41 |
P/E ratio | -8.72 x | -5.1 x | -6.67 x | -15.6 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | 51.1 x | 28.8 x | 5.61 x |
EV / Revenue | - | 43.2 x | 23.2 x | 4.81 x |
EV / EBITDA | - | -5.05 x | -5.23 x | -14.6 x |
EV / FCF | - | -4.75 x | -5.08 x | -13.6 x |
FCF Yield | - | -21.1% | -19.7% | -7.36% |
Price to Book | - | 2.5 x | 2.5 x | 5 x |
Nbr of stocks (in thousands) | 92,019 | 92,019 | - | - |
Reference price 2 | 0.8500 | 0.5000 | 0.5000 | 0.5000 |
Announcement Date | 29/08/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | 0.9 | 1.6 | 8.2 |
EBITDA 1 | - | -7.7 | -7.1 | -2.7 |
EBIT 1 | - | -9 | -8.4 | -3.9 |
Operating Margin | - | -1,000% | -525% | -47.56% |
Earnings before Tax (EBT) 1 | - | -9 | -8.4 | -3.9 |
Net income 1 | -8.969 | -9 | -8.4 | -3.9 |
Net margin | - | -1,000% | -525% | -47.56% |
EPS 2 | -0.0975 | -0.0980 | -0.0750 | -0.0320 |
Free Cash Flow 1 | - | -8.2 | -7.3 | -2.9 |
FCF margin | - | -911.11% | -456.25% | -35.37% |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 29/08/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | - | 7.1 | 8.9 | 6.6 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | -8.2 | -7.3 | -2.9 |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share 2 | - | 0.2000 | 0.2000 | 0.1000 |
Cash Flow per Share 2 | - | -0.0700 | -0.0600 | -0.0200 |
Capex 1 | - | 0.5 | 0.2 | 0.2 |
Capex / Sales | - | 55.56% | 12.5% | 2.44% |
Announcement Date | 29/08/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+33.37% | 49.46B | |
+1.56% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- IIQ Stock
- BD1 Stock
- Financials BAR1 LIFE